BofA Securities Reiterates Buy Rating on Ultragenyx Pharma (RARE): "current valuation undervalues the pipeline opportunity"
BofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $51.00 price target on Ultragenyx Pharma (NASDAQ: RARE)The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)